Breast Cancer Therapy Market Segmentation by Therapy (Hormonal Therapy, Targeted Therapy, Immunotherapy, and Chemotherapy); by Cancer Type [In situ {Ductal Carcinoma In Situ (DCIS)}, and Invasive {Invasive Ductal Carcinoma (IDC), and Invasive Lobular Carcinoma (ILC)}]; and by Route of Administration (Oral, and Injectable)-Global Demand Analysis & Opportunity Outlook 2031
-
Product Code:
RP-ID-10070786 -
Published Date:
21 Oct 2022 -
Region:
Global
-
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-54
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
Global Breast Cancer Therapy Market Highlights Over 2022 - 2031
The global breast cancer therapy market generated a revenue figure of approximately USD 26 billion in the year 2021 and is projected to grow at a CAGR of ~10% over the forecast period, i.e., 2022 – 2031. The growth of the market can primarily be attributed to the growing incidences of breast cancer, and budding investment in research and development of technology for cancer treatment. According to the World Health Organization (WHO), in the year 2020, 2.3 million women were diagnosed with breast cancer worldwide. According to the American Cancer Society Inc., in the United States, average risk for a woman to develop breast cancer at any point of life is about 13%. Moreover, the development & launch of new screening programs, and introduction of new pharmaceutical drugs for the cancerous treatment is expected to drive the market growth. Further, the initiatives taken by government to spread awareness about the treatment options and organizing free camps and workshops is projected to boost the market growth.
CLICK TO DOWNLOAD A SAMPLE REPORT
Breast cancer is cancer that develops in the breast and spreads to other parts of the body. It can begin in either one or both of the breasts. The breast is an organ located over the upper ribs and chest muscles. A lump in the breast, blood flow from the nipple, and changes in the form or texture of the nipple or breast are all signs of breast cancer.
The global breast cancer therapy market is segmented on the basis of therapy, cancer type, and route of administration. Among these, the therapy segment is divided into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. The targeted therapy segment is anticipated to hold the largest market size in value and is estimated to grow at a notable CAGR over the forecast period. Targeted therapies are drugs or elements that stop the spread of cancer by creating interference with specific molecules that helps in the growth and progression of cancer. The growth of the segment can be associated with the versatile nature of targeted therapy to pool with other therapies in order to show effective results against cancer disease. Moreover, the research and development in clinical studies for targeted therapy is anticipated to create major opportunities for the growth of the segment in the coming years.
Global Breast Cancer Therapy Market Regional Synopsis
Regionally, the global breast cancer therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America held the largest market share in the year 2021 as a result of the growing prevalence of breast cancer and developed healthcare infrastructure. In the other statistics by the American Cancer Society, Inc., in the United States, nearly 1 in 3 females are diagnosed with breast cancer each year. Besides, increased investment by pharmaceuticals company in research and development along with the rapid adoption of new technologies among healthcare professionals are major factors driving the market growth in this region. Alternatively, the market in the Asia Pacific region is projected to witness rapid growth by growing at a higher CAGR over the forecast period. The growth of the market can be attributed to the constant development in healthcare infrastructure, along with the government’s support services and initiatives to create awareness regarding cancer treatment among the public. Further, the rising cases of breast cancer in the region are expected to boost the market growth majorly in this region. According to the Organization for Economic Co-operation and Development (OECD), nearly 839000 women were diagnosed with breast cancer in the year 2018 in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global breast cancer therapy market includes the following segments:
By Therapy
-
Hormonal Therapy
-
Targeted Therapy
-
Immunotherapy
-
Chemotherapy
By Cancer Type
- In situ
-
Ductal Carcinoma In situ (DCIS)
- Invasive
-
Invasive Ductal Carcinoma (IDC)
-
Invasive Lobular Carcinoma (ILC)
By Route of Administration
-
Oral
-
Injectable
Growth Drivers and Challenges Impacting the Growth of the Global Breast Cancer Therapy Market
Growth Drivers
-
Growing cases of breast cancer
-
Increasing investment in research and development
-
Rapid launch of new screening programs
-
Growing development of pharmaceutical drugs
-
Support initiatives by the government in spreading awareness
Challenges
-
High cost of treatment
-
Concern for aftereffects of therapy
Key Companies Dominating the Global Breast Cancer Therapy Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global breast cancer therapy market that are included in our report are Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., PerkinElmer Inc., and Zimmer Biomet among others.
Latest Developments in the Global Breast Cancer Therapy Market:
-
11 March 2022: AstraZeneca and Merck announced that the U.S Food and Drug Administration (FDA), has approved LYNPARZA for adjuvant treatment for patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have received neoadjuvant or adjuvant chemotherapy in the past.
-
13 June 2019: The U.S. Food and Drug Administration (FDA) approved KANJINTI, developed by Amgen and Allergan plc to treat patients with HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
Geography Analysis:
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
.
FREQUENTLY ASKED QUESTIONS
Growing cases of breast cancer, investment in R&D, launch of new screening programs, development of pharmaceutical drugs, and supportive initiatives by government in spreading awareness are the major factors driving the market growth.
The market is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2022-2031.
High cost of treatment and concern for aftereffects of therapy are estimated to hamper the market growth.
Asia pacific region will provide more business opportunities for growth of breast cancer therapy market in future.
The major players in the market are Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., PerkinElmer Inc., and Zimmer Biomet among others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by therapy, cancer type, route of administration, and by region.
The targeted therapy segment is anticipated to hold largest market size in value and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Please enter your personal details below
- Amgen Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co.Inc.
- Novartis AG
- Pfizer Inc.
- PerkinElmer Inc.
- Zimmer Biomet